|
|
|
| Comparison of efficacy of Cefuroxime and Amoxicillin in the eradication treatment of Helicobacter pylori |
| LIU Minzhi LI Yunze WEI Tianling CAI Huaiyang QIN Min |
| Department of Gastroenterology, Liuzhou People’s Hospital, Guangxi Zhuang Autonomous Region, Liuzhou 545006,China |
|
|
|
Abstract Objective To compare the efficacy and safety of Cefuroxime and Amoxicillin in the eradication treatment of Helicobacter pylori (Hp). Methods A total of 160 patients diagnosed with Hp infection in the Outpatient Department of Liuzhou People’s Hospital of Guangxi Zhuang Autonomous Region from December 2017 to July 2020 were selected as the research subjects. Among them, 80 were initially treated patients who had not received previous Hp eradication treatment, and 80 patients were treated with bismuth drug quadruple regimen for 14 days to eradicate Hp after treatment failure. According to random number table method they were divided into treated first Cefuroxime, first Amoxicillin group and re-treat Cefuroxime and re-treat Amoxicillin group, with 40 cases in each group. Based on Rabeprazole, Furazolidone, and Colloidal bismuth pectin, combination respectively Cefuroxime or Amoxicillin Hp eradication therapy, treatment discontinuation ended at least four weeks after the review of Hp. The eradication rate of Hp and the incidence of adverse reactions in each group were compared. Results There was no significant difference in the eradication rate of Hp between first Cefuroxime group and first Amoxicillin group (P ＞ 0.05). There was no significant difference in the eradication rate of Hp between the re-treat Cefuroxime group and the re-treat Amoxicillin group (P ＞ 0.05). There was no statistical significance in the total incidence of adverse reactions among all groups (P ＞ 0.05). Conclusion There is no significant difference in the eradication rate of Hp between the quadruple therapy containing Cefuroxime and Amoxicillin, and similar eradication rates are obtained for both initial treatment and retreatment. For some patients who are not suitable for Penicillin, Cefuroxime may be a good alternative to Amoxicillin.
|
|
|
|
|
|
[1] Zhang YX，Zhou LY，Song ZQ，et al. Primary antibiotic resistance of Helicobacter pylori strains isolated from patients with dyspeptic symptoms in Beijing：a prospective serial study [J]. World J Gastroenterol，2015，21（9）：2786-2792.
[2] Su P，Li Y，Li H，et al. Antibiotic resistance of Helicobacter pylori isolated in the Southeast Coastal Region of China [J]. Helicobacter，2013，18（4）：274-279.
[3] Liang X，Xu X，Zheng Q，et al. Efficacy of bismuth-containing quadruple therapies for clarithromycin，metronidazole，and fluoroquinolone-resistant Helicobacter pylori infections in a prospective study [J]. Clin Gastroenterol Hepatol，2013，11（7）：802-807.
[4] Chen Q，Zhang W，Fu Q，et al. Rescue Therapy for Helicobacter pylori Eradication： A Randomized Non-Inferiority Trial of Amoxicillin or Tetracycline in Bismuth Quadruple Therapy [J]. Am J Gastroenterol，2016，111（12）：1736-1742.
[5] 陈国裕，陈锡美，沈洪亮，等.头孢类抗生素对根除失败者幽门螺杆菌药敏情况的研究[J].中国医药指南，2011， 9（26）：221-223.
[6] 李灿，闫盈盈，翟所迪.比较头孢菌素与青霉素类用于幽门螺杆菌根除的荟萃分析[J].中国临床药理学杂志，2014， 30（4）：350-353.
[7] 中华医学会消化病学分会幽门螺杆菌和消化性溃疡学组，全国幽门螺杆菌研究协作组，刘文忠，等.第五次全国幽门螺杆菌感染处理共识报告[J].中华消化杂志，2017， 37（6）：364-378.
[8] Hooi JKY，Lai WY，Ng WK，et al. Global prevalence of helicobacter pylori infection：Systematic review and meta-ananlysis [J]. Gastroenterology，2017，15（2）：420-429．
[9] Hu Y，Zhu Y，Lu NH. Primary antibiotic resistance of helicobacter pylori in China [J]. Dig Dis Sci，2017，62（5）：1146-1154．
[10] Zhang YW，Hu WL，Cai Y，et al. Outcomes of furazolidone-and amoxicillin-based quadruple therapy for Helicobacter pylori infection and predictors of failed eradication [J]. World J Gastroenterol，2018，24（40）：4596-4605．
[11] 晁帅恒，周炳喜，李修岭，等．呋喃唑酮四联方案在幽门螺杆菌感染补救治疗中的疗效及安全性评估[J].河南医学研究，2018，27（12）：2113-2115．
[12] 龚清全，何张平，郭智伟，等.阿莫西林、呋喃唑酮联合胶体果胶铋、泮托拉唑抗幽门螺杆菌疗效分析[J].海峡药学，2019，31（12）：162-164.
[13] Shen XH，Wang ZW，Gong Y，et al. Effect of different therapies to eradicate Helicobacter pylori [J]. Practical Pharmacy and Clinical Remedies，2017，20（4）：390-393.
[14] Song ZQ，Zhang JZ，He LH，et al． Prospective multi-region study on primary antibiotic resistance of Helicobacter pylori strains isolated from Chinese patients[J]. Dig Liver Dis，2014，46（12）：1077-1081．
[15] 杨宝峰，陈建国.药理学[M].9版.北京：人民卫生出版社，2018：375-376.
[16] Campagna JD，Bond MC，Schabelman E，et al. The use of cephalosporins in penicillin-allergic patients：A literature review [J]. J Emerg Med，2012，42（5）：612-620.
[17] Bai P，Zhou LY，Xiao XM，et al. Susceptibility of Helicobacter pylori to antibioticsin Chinese patients [J]. J Dig Dis，2015，16：464-470．
[18] Fagoonee S，Astegiano M，Smedile A，et al. Efficacy of cefixime-based triple therapy for Helicobacter pylori eradication：a restrospective therapy study [J]. Panminerva Med，2013，55（3）：309-310.
[19] Pichichero ME. Use of selected cephalosporins in penicillin-allergic patients：A paradigm shift [J]. Diagn Microbiol Infect Dis，2007，57（3 Suppl）：13S-18S.
[20] Miranda A，Blanca M，Vega JM，et al. Cross-reactivity between a penicillin and a cephalosporin with the same side chain [J]. J Allergy Clin Immunol，1996，98（3）：671-677.
[21] 国家药典委员会.中华人民共和国药典[S].二部.北京：中国医药科技出版社，2020：317-320.
[22] 国家药典委员会.中华人民共和国药典临床用药须知 化学药和生物制品卷[S].北京：中国医药科技出版社，2015：662-663.
[23] 抗菌药物临床应用指导原则修订工作组.抗菌药物临床应用指导原则：2015[M].北京：人民卫生出版社，2015：21-22.
[24] 陈新谦，金有豫，汤光.新编药物学[M].18版.北京：人民卫生出版社，2019：49-51.
[25] 北京药学会抗生素专业委员会.头孢类抗菌药物皮肤过敏试验高端论坛专家共识[J].临床药物治疗杂志，2008，6（4）：1-2. |
|
|
|
